Search results
Results from the WOW.Com Content Network
Participants were randomly assigned to receive either pravastatin (40 mg daily) or a placebo. The primary endpoint was the incidence of nonfatal myocardial infarction and death from CHD. Secondary endpoints included all-cause mortality, coronary revascularization procedures, and stroke.
Pravastatin, sold under the brand name Pravachol among others, is a statin medication, used for preventing cardiovascular disease in those at high risk and treating abnormal lipids. [5] It is suggested to be used together with diet changes, exercise, and weight loss. [ 5 ]
No studies have examined the effect of statins on cognition in patients with prior stroke. However, two large studies (HPS and PROSPER) that included people with vascular diseases reported that simvastatin and pravastatin did not impact cognition. [40] Statins have been studied for improving operative outcomes in cardiac and vascular surgery. [41]
Stroke is the third leading cause of death around the world, according to a November 2018 study, causing around 5.5 million deaths annually. “A stroke occurs when the central nervous system is ...
The so-called "classical 3-point MACE" is defined as a composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death. [4] [5] But another study defines MACE as "CVD events, admission for HF (Heart Failure), ischemic cardiovascular [CV] events, cardiac death, or MACE". [6]
After declining from 2002 to 2012, stroke death rates for middle-aged adults increased 7% between 2012 and 2019, and increased an additional 12% through 2021, the CDC found. The stroke death rate ...
Stroke is the second leading cause of death around the world, according to the World Health Organization, causing 6.6 million deaths in 2020. That number is expected to hit 9.7 million in 2050 ...
JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).